AQR Capital Management’s Dyne Therapeutics DYN Stock Holding History

AQR Capital Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.87M	Sell	84,054 -184	-0.2%	-$3.42K	﹤0.01%	2666
2026 Q1	$1.53M	Buy	84,238 +13,579	+19%	+$234K	﹤0.01%	2529
2025 Q4	$1.38M	Sell	70,659 -71,216	-50%	-$1.35M	﹤0.01%	2367
2025 Q3	$1.79M	Buy	141,875 +98,965	+231%	+$1.13M	﹤0.01%	2038
2025 Q2	$409K	Buy	42,910 +19,350	+82%	+$213K	﹤0.01%	2718
2025 Q1	$246K	Buy	+23,560	New	+$337K	﹤0.01%	2781
2024 Q4	–	Sell	-89,198	Closed	-$3.2M	–	2891
2024 Q3	$3.2M	Buy	89,198 +80,703	+950%	+$3.21M	﹤0.01%	1262
2024 Q2	$300K	Buy	8,495 +352	+4%	+$10.2K	﹤0.01%	2268
2024 Q1	$231K	Buy	+8,143	New	+$184K	﹤0.01%	2219
2023 Q4	–	Sell	-11,644	Closed	-$104K	–	2354
2023 Q3	$104K	Sell	11,644 -8,525	-42%	-$91.8K	﹤0.01%	2226
2023 Q2	$227K	Buy	+20,169	New	+$238K	﹤0.01%	2047

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management's DYN Position: Q2 2026 in Review

AQR Capital Management reduced its Dyne Therapeutics (DYN) stake by 0.22% in Q2 2026, selling an estimated $3.42K and leaving 84,054 shares worth $1.87M. The position accounts for ﹤0.01% of the portfolio, ranked #2666.

AQR Capital Management first reported a position in DYN in Q2 2023 and has held it in 11 quarters since. The position peaked at $3.2M in Q3 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

AQR Capital Management held 84,054 shares of Dyne Therapeutics worth $1.87M as of Q2 2026.
AQR Capital Management sold 184 Dyne Therapeutics shares in Q2 2026, an estimated $3.42K.
Dyne Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2666 holding.
AQR Capital Management first reported a position in Dyne Therapeutics in Q2 2023 and has held it in 11 quarters since.
AQR Capital Management's Dyne Therapeutics position peaked at $3.2M in Q3 2024.
245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.